Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Stake Held by Bp Plc

Bp Plc continued to hold its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the second quarter, Holdings Channel reports. The fund owned 26,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Bp Plc’s holdings in Alexion Pharmaceuticals were worth $3,163,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Seven Bridges Advisors LLC raised its position in shares of Alexion Pharmaceuticals by 2.1% in the second quarter. Seven Bridges Advisors LLC now owns 2,638 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 53 shares during the last quarter. TD Asset Management Inc. raised its position in shares of Alexion Pharmaceuticals by 10.3% in the second quarter. TD Asset Management Inc. now owns 397,087 shares of the biopharmaceutical company’s stock valued at $48,314,000 after buying an additional 37,028 shares during the last quarter. Candriam Luxembourg S.C.A. raised its position in shares of Alexion Pharmaceuticals by 6.1% in the second quarter. Candriam Luxembourg S.C.A. now owns 222,098 shares of the biopharmaceutical company’s stock valued at $27,024,000 after buying an additional 12,701 shares during the last quarter. IPG Investment Advisors LLC bought a new position in shares of Alexion Pharmaceuticals during the second quarter valued at $208,000. Finally, Daiwa Securities Group Inc. raised its position in shares of Alexion Pharmaceuticals by 3.3% in the second quarter. Daiwa Securities Group Inc. now owns 6,300 shares of the biopharmaceutical company’s stock valued at $767,000 after buying an additional 200 shares during the last quarter. Institutional investors own 95.14% of the company’s stock.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 136.85 on Thursday. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $145.42. The company’s 50 day moving average is $128.92 and its 200 day moving average is $122.85. The stock has a market cap of $30.54 billion, a P/E ratio of 59.35 and a beta of 1.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.48. The business had revenue of $912 million for the quarter, compared to the consensus estimate of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same period last year, the firm posted $1.13 earnings per share. Equities analysts predict that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Stake Held by Bp Plc” was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/2798600/alexion-pharmaceuticals-inc-nasdaqalxn-stake-held-by-bp-plc.html.

Several research analysts have weighed in on the stock. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 5th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 target price on the stock in a research report on Wednesday, August 2nd. BMO Capital Markets restated an “outperform” rating and set a $168.00 target price (up from $159.00) on shares of Alexion Pharmaceuticals in a research report on Friday, July 28th. Leerink Swann upped their target price on shares of Alexion Pharmaceuticals from $136.00 to $170.00 and gave the stock an “outperform” rating in a research report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. upgraded shares of Alexion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $175.00 target price on the stock in a research report on Friday, July 28th. Five equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $156.89.

In other news, Director Ann M. Veneman sold 700 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $137.74, for a total value of $96,418.00. Following the transaction, the director now directly owns 6,315 shares of the company’s stock, valued at $869,828.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Ludwig Hantson bought 10,000 shares of the company’s stock in a transaction dated Wednesday, June 14th. The stock was purchased at an average cost of $116.72 per share, for a total transaction of $1,167,200.00. Following the completion of the transaction, the chief executive officer now owns 38,725 shares of the company’s stock, valued at $4,519,982. The disclosure for this purchase can be found here. Over the last three months, insiders bought 2,019,734 shares of company stock worth $235,606,846. 4.35% of the stock is currently owned by insiders.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.